காஸ்ட்ரோ ஜூனியர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காஸ்ட்ரோ ஜூனியர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காஸ்ட்ரோ ஜூனியர் Today - Breaking & Trending Today

Lyford police seeks missing man


Lyford police seeks missing man
1 week 20 hours 48 minutes ago
Friday, May 14 2021
May 14, 2021
May 14, 2021 3:50 PM
May 14, 2021
in
News
By: KRGV Digital
Share:
The Lyford Police Department continues to search for a man who has been missing for nearly three weeks.
Angel Castro Jr., 22, was last seen on Sunday, April 25 walking south from FM 498 toward Harlingen, the Lyford Police Department said in a social media post.
He was last seen wearing a sombrero, a black t-shirt, black pants, dark brown construction boots and carrying three duffle bags.
Those with information on Castro Jr.’s whereabouts are urged to contact the Lyford Police Department at 956-347-3250 or the Willacy County Sheriff’s Office at 956-689-5576. ....

Angel Castro Jr , Castro Jr , Lyford Police Department , Willacy County Sheriff Office , Willacy County Sheriff , காஸ்ட்ரோ ஜூனியர் , லைஃபோர்ட் போலீஸ் துறை , வில்லாசி கவுண்டி ஷெரிப் அலுவலகம் , வில்லாசி கவுண்டி ஷெரிப் ,

Mountain Valley MD Proceeding With Pre-Clinical Cancer Trials, Files Related Cancer Patent


Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
 Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma. ....

Xianquan Zhan , Zhijun Zhao , Liang Chen , Castro Jr , Fernanda Saldivar , Julia Aguade Gorgorio , Caterina Mezzatesta , Mingyang Tang , Chen Ying Yu , Mike Farber , Guadalupe Dominguez , Jose Luis Medina , Martin Stanulla , Blerim Marovca , Silvia Jenni , Qiuren Wei , Anna Guinot , Jana Burger , Qiang Fang , Jiangyan Li , Xin Yao , Martin Schrappe , Zhen Han , Fuying Cheng , Liridon Abduli , Darrellj Irvine ,